IXICO has announced a strategic collaboration with Medidata, combining IXICO's neuroimaging analytics with Medidata's global clinical trial platform to create a seamless solution for biopharma trials. CEO Bram Goorden described the partnership as a significant step into the "tech bio" space. Medidata serves 18 of the top 25 pharmaceutical companies and supports around 38,000 trials across 140 geographies. The collaboration gives IXICO access to larger, more complex trials and is expected to generate recurring revenue streams. The deal follows recent contract wins, including a £1.5 million Phase 2 trial extension, and the appointment of Tanya Voloshen as Chief Commercial Officer. Goorden said the partnership marks a new chapter for the imaging contract research organisation, positioning it to scale whilst maintaining its core business focus.

Medidata, a Dassault Systèmes brand, has expanded its partnership with The Menarini Group and its subsidiary Stemline Therapeutics to accelerate oncology clinical trials using AI Study Build technology. The technology leverages data from over 38,000 trials to automate configurations, reducing the time between protocol finalisation and trial startup from months to weeks. Stemline recently launched its first oncology study entirely in-house using Medidata's platform. The AI-powered system enables rapid study startups, internal agility for building future trials independently, and faster delivery of high-quality data for cancer research. The expansion builds on a 14-year relationship between Menarini and Medidata. Whilst Menarini has long used Medidata's platform including Rave EDC and eCOA, the adoption of AI Study Build marks a significant advancement in streamlining clinical trial workflows.

Medidata, a Dassault Systèmes brand providing clinical trial solutions, has deployed AI technology across over 500 clinical studies in the past decade, with more than 120 AI-supported studies launching in 2025 alone. The company has introduced Medidata AI Study Build, which uses generative AI to configure trial systems by leveraging study protocols, significantly reducing time from protocol to start-up. The technology draws on data from more than 38,000 trials to accelerate clinical development. Medidata is expanding Dot, its AI orchestrator that connects domain-specific AI capabilities across its platform. The company's unified platform aims to streamline complex database builds and accelerate market access for new therapies. Medidata serves approximately 2,300 customers with over 1 million registered users.